Abbott Laboratories (NYSE: ABT) stock was in fine health on the second-to-last trading day of the week, thanks to news from ...

Shares of Abbott Laboratories advanced 3.74% to $131.35 Thursday, on what proved to be an all-around poor trading session for ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

We recently published a list of Diamond Hill Capital Stock Portfolio: Top 10 Stock Picks. In this article, we are going to ...

In a report released today, Joanne Wuensch from Citi maintained a Buy rating on Abbott Laboratories (ABT – Research Report). The company’s ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.

Abbott Laboratories closed 10.57% short of its 52-week high of $141.23, which the company reached on March 4th.

Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the ...